Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:49 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2257–2280 of 10,535 matching trials from the live ClinicalTrials.gov search.

Filters: Active, not recruiting Clear all

Conditions: Prostate Cancer, Oligometastatic Disease
Interventions: niraparib/abiraterone acetate, Stereotactic ablative radiation therapy (SABR), Androgen deprivation therapy (ADT); Drug · Radiation
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older · Male only
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cancer, Major Depressive Disorder
Interventions: Psilocybin, Placebo; Drug
Lead sponsor: Sunstone Medical; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Osteoarthritis, Knee
Interventions: Zero Degree Knee Positioner; Device
Lead sponsor: Prisma Health-Midlands; Other
Eligibility: 40 Years to 80 Years
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Columbia, South Carolina

Conditions: Breast Cancer, Cancer Survivor
Interventions: educational intervention, counseling intervention, standard follow-up care, quality-of-life assessment, questionnaire administration; Other · Procedure
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2027
U.S. locations: 2
States / cities: Duarte, California • Lancaster, California

Conditions: Physical Disability
Interventions: Virtually supervised exercise, Health education; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Alzheimer Disease
Interventions: OLX-07010 Active, OLX-07010 Placebo; Drug
Lead sponsor: Oligomerix, Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Glendale, California

Conditions: Fabry Disease, Fabry Disease, Cardiac Variant
Interventions: ST-920; Biological
Lead sponsor: Sangamo Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2039
U.S. locations: 8
States / cities: Irvine, California • Tampa, Florida • Atlanta, Georgia + 5 more

Conditions: Malignant Pleural Mesothelioma
Interventions: Pembrolizumab, IMPRINT; Drug · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Diabetic Retinopathy (DR)
Interventions: Diabetic Retinopathy screening Point of Care Artificial Intelligence; Diagnostic Test
Lead sponsor: Centro De Salud La Comunidad De San Ysidro Inc DBA: San Ysidro Health; Other
Eligibility: 22 Years and older
Enrollment: 548 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 3
States / cities: Chula Vista, California • San Diego, California

Conditions: Anterior Cruciate Ligament Injury, Anterior Cruciate Ligament Rupture
Interventions: Bridge-Enhanced ACL Restoration (BEAR); Device
Lead sponsor: Miach Orthopaedics; Industry
Eligibility: 12 Years to 80 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2034
U.S. locations: 11
States / cities: San Diego, California • Tampa, Florida • Atlanta, Georgia + 8 more

Conditions: Healthy, Normal Weight, Overweight, Obese
Interventions: High-polyphenol olive oil, Low-polyphenol olive oil; Dietary Supplement
Lead sponsor: University of California, Davis; Other
Eligibility: 20 Years to 45 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Davis, California

Conditions: Spinal Cord Injuries
Interventions: High Dose Intervention-tsDCS, Low Dose Intervention-tsDCS; Device
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Advanced Solid Tumor, Metastatic Solid Tumors
Interventions: Raludotatug deruxtecan; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 335 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 8
States / cities: Marietta, Georgia • Ann Arbor, Michigan • East Brunswick, New Jersey + 5 more

Conditions: Endogenous Cushing's Syndrome
Interventions: Osilodrostat; Drug
Lead sponsor: RECORDATI GROUP; Industry
Eligibility: 18 Years and older
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 15
States / cities: Phoenix, Arizona • Atlanta, Georgia • Chicago, Illinois + 11 more

Conditions: Wilson Disease
Interventions: Not listed
Lead sponsor: Prime Medicine, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 7
States / cities: Los Angeles, California • Sacramento, California • New Haven, Connecticut + 4 more

Conditions: Ovarian Cancer
Interventions: olaparib, paclitaxel, carboplatin, Drug: carboplatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 125 Years · Female only
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2026
U.S. locations: 8
States / cities: Stanford, California • West Hollywood, California • Orlando, Florida + 4 more

Conditions: Bladder Cancer
Interventions: TAR-200, Cetrelimab, BCG Vesiculture; Drug · Biological
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 51
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • Long Beach, California + 42 more

Conditions: Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Panitumumab, Sotorasib; Procedure · Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 180
States / cities: Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 135 more

Conditions: Glioblastoma
Interventions: INO-5401, INO-9012, Cemiplimab, Radiation Therapy, Temozolomide; Biological · Radiation · Drug
Lead sponsor: Inovio Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 21
States / cities: Duarte, California • Palo Alto, California • San Francisco, California + 15 more

Conditions: Diabetic Macular Edema
Interventions: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab, Intravitreal Ranibizumab 0.5 mg Injection, Ranibizumab refill exchange; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 672 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 89
States / cities: Mesa, Arizona • Phoenix, Arizona • Bakersfield, California + 79 more

Conditions: Cerebral Palsy
Interventions: Clinical Assessments, Brain-Spinal Cord fMRI, Hoffmann Reflex Assessments, MEG Imaging, Transcutaneous Current Stimulation; Behavioral
Lead sponsor: Father Flanagan's Boys' Home; Other
Eligibility: 11 Years to 45 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Boys Town, Nebraska

Conditions: Critical Limb Ischemia (CLI)
Interventions: Esprit BTK Device; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 3
States / cities: Jacksonville, Florida • South Dartmouth, Massachusetts • Bartlesville, Oklahoma

Conditions: Recurrent Cervix Cancer, Progressive Cervix Cancer
Interventions: Niraparib, dostarlimab; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years and older · Female only
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 4
States / cities: Indianapolis, Indiana • New Orleans, Louisiana • Oklahoma City, Oklahoma + 1 more

Conditions: Vaccinia, Virus Diseases
Interventions: JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) suspension for subcutaneous injection, Phlebotomy, Research bronchoscopy, Skin punch biopsy, Bone marrow aspiration; Biological · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Search by objective public record fields.

High-Risk Metachronous Oligometastatic Prostate Cancer Trial

Two Doses of Psilocybin for the Treatment of MDD in Adults With Cancer

Zero Degree Knee Positioner for Improved Earley Knee Extension Following Total Knee Arthroplasty

Survivorship Care Planning in Improving the Quality of Life in Breast Cancer Survivors

Virtually Supervised Exercise for Kidney Transplant Candidates

Phase 1 Study of OLX-07010 in Healthy Adult and Elderly Participants

Long-Term Follow-up of Subjects Who Were Treated With ST-920

A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma

Diabetic Retinopathy Screening Point-of-Care Artificial Intelligence

The BEAR III Trial for Bridge-Enhanced ACL (Anterior Cruciate Ligament) Restoration

Olive Oil Polyphenols and Cardiovascular Health Biomarkers

AMPLIFY Study: Transcutaneous Spinal Direct Current Stimulation to Enhance Locomotor Rehabilitation After SCI

A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)

Non-interventional Study on Osilodrostat in Patients With Endogenous Cushing's Syndrome

Prescreening Study to Identify Potential Wilson Disease Participants for Gene-Editing Clinical Trial

Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer

A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)

Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)

INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)

A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME

Neuromodulation of the Cortex and Spinal Cord

LIFE-BTK PK Sub-study

Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer

Evaluating the Human Immune Response to the JYNNEOS Vaccine